A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Ejemel, Monir, Li, Qi, Hou, Shurong, Schiller, Zachary A., Tree, Julia A., Wallace, Aaron, Amcheslavsky, Alla, Kurt Yilmaz, Nese, Buttigieg, Karen R., Elmore, Michael J., Godwin, Kerry, Coombes, Naomi, Toomey, Jacqueline R., Schneider, Ryan, Ramchetty, Anudeep S., Close, Brianna J., Chen, Da-Yuan, Conway, Hasahn L., Saeed, Mohsan, Ganesa, Chandrashekar, Carroll, Miles W., Cavacini, Lisa A., Klempner, Mark S., Schiffer, Celia A., Wang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442812/
https://www.ncbi.nlm.nih.gov/pubmed/32826914
http://dx.doi.org/10.1038/s41467-020-18058-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442812/
https://www.ncbi.nlm.nih.gov/pubmed/32826914
http://dx.doi.org/10.1038/s41467-020-18058-8

Ejemplares similares